NOI - DNA Sequencing of Bone Marrow Failure Syndro
Updated
Solicitation from the National Institutes of Health. Due Nov 2, 2026, 9:00 AM (UTC-5), 10 days left.
| Solicitation number | 75N98027Q00027 |
|---|---|
| Agency | National Institutes of Health |
| Office | National Institutes of Health Olao |
| Notice type | Solicitation |
| Set-aside | None |
| Trade (NAICS) | In-Vitro Diagnostic Substance Manufacturing (325413) |
| Product or service code | 6550 |
| Posted | Oct 22, 2026 |
| Response deadline | Nov 2, 2026, 9:00 AM (UTC-5) (10 days left) |
| Add the deadline to | Google Calendar · Apple / Outlook (.ics) |
Official notice and attachments
Description
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027.
This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold.
Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits.
Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline.
All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees.
This requirement is not set aside for small business.
Contracting contact
- Capobianco, Nicholas S · [email protected] · +1 000 000 0000
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
Is your business small enough?
For NAICS 325413, a business counts as small if it has no more than 1,250 employees (SBA size standard). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.
Companies that win this kind of work
Federal contractors paid for in-vitro diagnostic substance manufacturing work, who also hold NIH contracts (last 12 months): possible competitors, or partners to team with.
- Cepheid $34.9 million in this trade
- Biomerieux Inc $34.6 million in this trade
- Roche Diagnostics Corporation $20.9 million in this trade
- Abbott Laboratories Inc. $4.8 million in this trade
- Quest Diagnostics Incorporated $4.4 million in this trade
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.
In-Vitro Diagnostic Substance Manufacturing contracts right now
There are 19 open government contract opportunities in this trade (NAICS 325413), 7 posted in the last 7 days; 37% are set aside for small businesses. The agencies buying the most are Department of Veterans Affairs, National Institutes of Health and Defense Health Agency (DHA). Most of the work with a stated place is in Washington, Maryland and Texas. A notice in this trade gives a median of 11 days from posting to deadline; this one gives 11 days.
All open in-vitro diagnostic substance manufacturing contracts
Recent awards in this trade
- Abbott Molecular Inc. $919,866 · Department of Veterans Affairs · Oct 6, 2026
- Werfen USA LLC $345,941 · Department of Veterans Affairs · Oct 1, 2026
- Werfen USA LLC $69,188 · Department of Veterans Affairs · Oct 1, 2026
- Biomerieux Inc $284,026 · Department of Veterans Affairs · Oct 1, 2026
- Abbott Laboratories Inc. $748,477 · Department of Veterans Affairs · Oct 1, 2026
From the award notices agencies publish.